Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension.

[1]  K. Ravid,et al.  Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms , 2023, Frontiers in Cell and Developmental Biology.

[2]  V. Hytönen,et al.  Hepcidin is potential regulator for renin activity , 2022, PloS one.

[3]  T. Stricker,et al.  Patient-specific comorbidities as prognostic variables for survival in myelofibrosis , 2022, Blood advances.

[4]  T. Kahan,et al.  The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19 , 2021, Frontiers in Pharmacology.

[5]  T. Barbui,et al.  Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. , 2020 .

[6]  R. Latagliata,et al.  Impact of comorbidities and body mass index on the outcome of polycythemia vera patients , 2020, Hematological oncology.

[7]  R. Foà,et al.  Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors , 2020, Annals of Hematology.

[8]  A. Tefferi,et al.  Pregnancy outcomes in myeloproliferative neoplasms: A Mayo Clinic report on 102 pregnancies , 2020, American journal of hematology.

[9]  V. Accurso,et al.  Cardiovascular risk factor in MPN patients , 2020, Journal of Thrombosis and Thrombolysis.

[10]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[11]  A. Rauf,et al.  Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[12]  T. Barbui,et al.  ACE inhibitors and cytoreductive therapy in polycythemia vera. , 2017, Blood.

[13]  Ivy Shiue,et al.  Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015 , 2017, JAMA.

[14]  M. Cazzola,et al.  The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera , 2017, American journal of hematology.

[15]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[16]  N. Milic,et al.  Predictors of survival and cause of death in patients with essential thrombocythemia , 2015, European journal of haematology.

[17]  S. Verstovsek,et al.  Comorbidities predict worse prognosis in patients with primary myelofibrosis , 2014, Cancer.

[18]  N. Milic,et al.  The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia , 2014, Medical Oncology.

[19]  R. Touyz,et al.  Angiotensin II and Vascular Injury , 2014, Current Hypertension Reports.

[20]  M. Cazzola,et al.  Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study , 2013, Leukemia.

[21]  R. Kralovics,et al.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. , 2013, Blood.

[22]  T. Barbui,et al.  Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). , 2012, Blood.

[23]  M. Cazzola,et al.  A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. , 2012, Blood.

[24]  T. Barbui,et al.  Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. , 2011, Blood.

[25]  T. Barbui,et al.  Thrombosis in primary myelofibrosis: incidence and risk factors. , 2009, Blood.

[26]  G. Barosi,et al.  Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders , 2008, Leukemia.

[27]  R. Kusec,et al.  Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status , 2007, Cancer biology & therapy.

[28]  A. Tefferi,et al.  Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients , 2007, Leukemia.

[29]  R. Kusec,et al.  Angiotensin I‐converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow , 2003, British journal of haematology.

[30]  E. Nemeth,et al.  Regulation of the Iron Homeostatic Hormone Hepcidin. , 2017, Advances in nutrition.